Rinaldi F, Marchesi F, Palombi F, et al. - Given all patients with diffuse large B-cell lymphoma (DLBCL) refractory to treatment can not be identified using the available prognostic tools, and microRNAs represent interesting candidates for non-invasive biomarkers, thus, researchers conducted this study wherein serum miR-22, an evolutionarily conserved microRNA, was validated as a prognostic/predictive biomarker in DLBCL. Furthermore, it was revealed that its expression as well as release from DLBCL cells were associated with treatment response and adversely influenced cell proliferation. These findings indicate a promising value of miR-22 as a complementary or even independent non-invasive biomarker for DLBCL management.